{'fraction_non_alphanumeric': 0.060806742925948225, 'fraction_numerical': 0.06622516556291391, 'mean_word_length': 4.852112676056338, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Relationship between expression of inhibitory killer cell immunoglobulin-like receptor HLA-Cw ligand and susceptibility to inflammatory bowel disease].

OBJECTIVE
To investigate the distribution of different phenotypes of inhibitory killer cell immunoglobulin-like receptor (iKIR) and its ligand HLA-Cw in patients with inflammatory bowel disease (IBD), and to explore whether iKIR/HLA-Cw combinations are associated with IBD susceptibility.


METHODS
Peripheral blood samples were collected from 100 patients with ulcerative colitis (UC), 73 patients with Crohn's disease, and 106 randomly selected ethnically matched healthy controls. Polymerase chain reaction with sequence-specific primers was used to analyze the iKIR phenotypes, and the HLA-Cw phenotypes was examined with HLA-C LOCUS SSP UNITRAY kit, and the combination of HLA-Cw and its corresponding iKIR in individual was analyzed subsequently.


RESULTS
The KIR2DL1 and KIR2DL3 gene phenotype frequencies in UC patients were 0.710 and 0.620 respectively, both significantly lower than those in healthy controls (0.896, chi(2) = 11.405 P = 0.001, and 0.821, chi(2) = 10.362 P = 0.001 respectively). The KIR2DL1 gene phenotype frequency in CD patients was 0.740, significantly lower than that in healthy controls (0.896, chi(2) = 7.589, P = 0.006). The KIR2DL1 HLA-C2 combination (2DL1(+)-HLA-C2(+)) in UC patients and CD patients were 0.380 and 0.411 respectively, both significantly lower than that in healthy controls (0.575, chi(2) = 7.876 P = 0.005 and 0.575, chi(2) = 4.681 P = 0.030 respectively).


CONCLUSION
The susceptibility to IBD is associated with decreased KIR2DL1-HLA-C2 combination.